Unknown

Dataset Information

0

First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer.

ABSTRACT:

SUBMITTER: Jeong BH 

PROVIDER: S-EPMC5879504 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer.

Jeong Byeong-Ho BH   Um Sang-Won SW  

Annals of translational medicine 20180201 3

Similar Datasets

Unknown Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer.
| S-EPMC9971254 | biostudies-literature
Unknown Osimertinib as first-line treatment of EGFR mutant advanced non-small-cell lung cancer.
| S-EPMC5750146 | biostudies-literature
Unknown Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer.
| S-EPMC10235017 | biostudies-literature
Unknown Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
| S-EPMC6143050 | biostudies-literature
Unknown First-line osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer: efficacy and safety during the COVID-19 pandemic.
| S-EPMC10413024 | biostudies-literature
Unknown Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance.
| S-EPMC10311169 | biostudies-literature
Unknown First-line treatments in EGFR-mutated advanced non-small cell lung cancer: A network meta-analysis.
| S-EPMC6776360 | biostudies-literature
Unknown Real-World Experience of First-Line Osimertinib in EGFR Mutated Non-Small Cell Lung Cancers from a Tertiary Cancer Center, India.
| S-EPMC12747758 | biostudies-literature
Unknown Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.
| S-EPMC6889286 | biostudies-literature
Unknown Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
| S-EPMC7209579 | biostudies-literature